Biosimilars

The FDA aims to reduce drug prices with a more competitive market - and generics are key.

John Lambert talks antibody-drug conjugates and his involvement with Kadcyla.

Will a pilot project to prequalify “generic” biologics improve safe access to medicines?

We forge ahead to celebrate the fantastic individuals involved in bettering the pharma industry.

Surface plasmon resonance has become a go-to tool for biotherapeutic characterization.

President Trump has the opportunity to get healthcare moving by boosting biogeneric use.

Sitting Down With... Fiona Greer, a biosimilar guru from SGS.

Could manufacturers based in Russia be well placed to develop cheaper biopharmaceuticals?

We investigate the advantages and limitations of microcalorimetry in biopharma.

How inspiration from the airline industry could help improve the biosimilars industry.